← 治験一覧に戻る
症状のある末梢動脈疾患患者が下肢末梢血管再建術を受ける際の、リバーロキサバンによる主要血栓性血管イベントリスク低減効果と安全性
基本情報
- NCT ID
- NCT02504216
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 6,564
- 治験依頼者名
- Bayer
概要
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.
対象疾患
Peripheral Artery Disease
介入
Rivaroxaban (Xarelto, BAY59-7939)(DRUG)
Rivaroxaban-Placebo(DRUG)